Development of High-Specificity Fluorescent Probes to Enable Cannabinoid Type 2 Receptor Studies in Living Cells.

Alzheimer Disease / metabolism Animals CHO Cells Cricetulus Disease Models, Animal Flow Cytometry Fluorescence Resonance Energy Transfer Fluorescent Dyes / chemistry Humans Ligands Mice Microglia / metabolism Molecular Docking Simulation Molecular Probes / chemistry Optical Imaging Receptor, Cannabinoid, CB2 / analysis Sensitivity and Specificity Signal Transduction

Journal

Journal of the American Chemical Society
ISSN: 1520-5126
Titre abrégé: J Am Chem Soc
Pays: United States
ID NLM: 7503056

Informations de publication

Date de publication:
07 10 2020
Historique:
pubmed: 10 9 2020
medline: 22 4 2021
entrez: 9 9 2020
Statut: ppublish

Résumé

Pharmacological modulation of cannabinoid type 2 receptor (CB

Identifiants

DOI: 10.1021/jacs.0c05587 PMID: 32902974
pubmed: 32902974
doi: 10.1021/jacs.0c05587
doi:

Substances chimiques

Fluorescent Dyes 0
Ligands 0
Molecular Probes 0
Receptor, Cannabinoid, CB2 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

16953-16964

Subventions

Organisme : NHLBI NIH HHS
ID : R01 HL139008
Pays : United States

Auteurs

Roman C Sarott (RC)

Laboratorium für Organische Chemie, Eidgenössische Technische Hochschule Zürich, Vladimir-Prelog-Weg 3, 8093 Zürich, Switzerland.
ORCID: 0000-0001-8789-6150

Matthias V Westphal (MV)

Laboratorium für Organische Chemie, Eidgenössische Technische Hochschule Zürich, Vladimir-Prelog-Weg 3, 8093 Zürich, Switzerland.

Patrick Pfaff (P)

Laboratorium für Organische Chemie, Eidgenössische Technische Hochschule Zürich, Vladimir-Prelog-Weg 3, 8093 Zürich, Switzerland.
ORCID: 0000-0002-9761-2497

Claudia Korn (C)

Roche Pharma Research & Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., 4070 Basel, Switzerland.

David A Sykes (DA)

Faculty of Medicine & Health Sciences, University of Nottingham, Nottingham NG7 2UH, U.K.
Centre of Membrane Proteins and Receptors (COMPARE), University of Birmingham and University of Nottingham, Midlands B15 2TT, U.K.

Thais Gazzi (T)

Leibniz-Institut für Molekulare Pharmakologie FMP, Campus Berlin-Buch, 13125 Berlin, Germany.

Benjamin Brennecke (B)

Leibniz-Institut für Molekulare Pharmakologie FMP, Campus Berlin-Buch, 13125 Berlin, Germany.

Kenneth Atz (K)

Roche Pharma Research & Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., 4070 Basel, Switzerland.

Marie Weise (M)

Leibniz-Institut für Molekulare Pharmakologie FMP, Campus Berlin-Buch, 13125 Berlin, Germany.

Yelena Mostinski (Y)

Leibniz-Institut für Molekulare Pharmakologie FMP, Campus Berlin-Buch, 13125 Berlin, Germany.

Pattarin Hompluem (P)

Faculty of Medicine & Health Sciences, University of Nottingham, Nottingham NG7 2UH, U.K.
Centre of Membrane Proteins and Receptors (COMPARE), University of Birmingham and University of Nottingham, Midlands B15 2TT, U.K.

Eline Koers (E)

Faculty of Medicine & Health Sciences, University of Nottingham, Nottingham NG7 2UH, U.K.
Centre of Membrane Proteins and Receptors (COMPARE), University of Birmingham and University of Nottingham, Midlands B15 2TT, U.K.

Tamara Miljuš (T)

Faculty of Medicine & Health Sciences, University of Nottingham, Nottingham NG7 2UH, U.K.
Centre of Membrane Proteins and Receptors (COMPARE), University of Birmingham and University of Nottingham, Midlands B15 2TT, U.K.

Nicolas J Roth (NJ)

William Harvey Research Institute, Barts and the London School of Medicine, Queen Mary University of London, London EC1M 6BQ, England.

Hermon Asmelash (H)

William Harvey Research Institute, Barts and the London School of Medicine, Queen Mary University of London, London EC1M 6BQ, England.

Man C Vong (MC)

Faculty of Medicine & Health Sciences, University of Nottingham, Nottingham NG7 2UH, U.K.
Centre of Membrane Proteins and Receptors (COMPARE), University of Birmingham and University of Nottingham, Midlands B15 2TT, U.K.

Jacopo Piovesan (J)

Faculty of Medicine & Health Sciences, University of Nottingham, Nottingham NG7 2UH, U.K.
Centre of Membrane Proteins and Receptors (COMPARE), University of Birmingham and University of Nottingham, Midlands B15 2TT, U.K.

Wolfgang Guba (W)

Roche Pharma Research & Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., 4070 Basel, Switzerland.

Arne C Rufer (AC)

Roche Pharma Research & Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., 4070 Basel, Switzerland.

Eric A Kusznir (EA)

Roche Pharma Research & Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., 4070 Basel, Switzerland.

Sylwia Huber (S)

Roche Pharma Research & Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., 4070 Basel, Switzerland.

Catarina Raposo (C)

Roche Pharma Research & Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., 4070 Basel, Switzerland.

Elisabeth A Zirwes (EA)

Roche Pharma Research & Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., 4070 Basel, Switzerland.

Anja Osterwald (A)

Roche Pharma Research & Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., 4070 Basel, Switzerland.

Anto Pavlovic (A)

Roche Pharma Research & Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., 4070 Basel, Switzerland.

Svenja Moes (S)

Roche Pharma Research & Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., 4070 Basel, Switzerland.

Jennifer Beck (J)

Roche Pharma Research & Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., 4070 Basel, Switzerland.

Irene Benito-Cuesta (I)

Faculty of Experimental Sciences, Universidad Francisco de Vitoria, Pozuelo de Alarcón, 28223, Madrid, Spain.

Teresa Grande (T)

Faculty of Experimental Sciences, Universidad Francisco de Vitoria, Pozuelo de Alarcón, 28223, Madrid, Spain.

Samuel Ruiz de Martı N Esteban (S)

Faculty of Experimental Sciences, Universidad Francisco de Vitoria, Pozuelo de Alarcón, 28223, Madrid, Spain.

Alexei Yeliseev (A)

National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Rockville, Maryland 20852, United States.

Faye Drawnel (F)

Roche Pharma Research & Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., 4070 Basel, Switzerland.

Gabriella Widmer (G)

Roche Pharma Research & Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., 4070 Basel, Switzerland.

Daniela Holzer (D)

Roche Pharma Research & Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., 4070 Basel, Switzerland.

Tom van der Wel (T)

Department of Molecular Physiology, Leiden Institute of Chemistry, Leiden University, 2333 CC, Leiden, The Netherlands.

Harpreet Mandhair (H)

Institute of Biochemistry and Molecular Medicine, University of Bern, 3012 Bern, Switzerland.

Cheng-Yin Yuan (CY)

Department of Microbiology and Immunology, Neuroscience Research Center, Medical College of Wisconsin, Milwaukee, Wisconsin 53226, United States.

William R Drobyski (WR)

Department of Medicine, Neuroscience Research Center, Medical College of Wisconsin, Milwaukee, Wisconsin 53226, United States.

Yurii Saroz (Y)

Department of Pharmacology and Clinical Pharmacology, School of Medical Sciences, Faculty of Medical and Health Sciences, University of Auckland, 1142 Auckland, New Zealand.

Natasha Grimsey (N)

Department of Pharmacology and Clinical Pharmacology, School of Medical Sciences, Faculty of Medical and Health Sciences, University of Auckland, 1142 Auckland, New Zealand.
ORCID: 0000-0003-3941-4537

Michael Honer (M)

Roche Pharma Research & Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., 4070 Basel, Switzerland.

Jürgen Fingerle (J)

Roche Pharma Research & Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., 4070 Basel, Switzerland.

Klaus Gawrisch (K)

National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Rockville, Maryland 20852, United States.

Julian Romero (J)

Faculty of Experimental Sciences, Universidad Francisco de Vitoria, Pozuelo de Alarcón, 28223, Madrid, Spain.

Cecilia J Hillard (CJ)

Department of Pharmacology and Clinical Pharmacology, Neuroscience Research Center, Medical College of Wisconsin, Milwaukee, Wisconsin 53226, United States.

Zoltan V Varga (ZV)

National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Rockville, Maryland 20852, United States.
HCEMM-SU Cardiometabolic Immunology Research Group, Department of Pharmacology and Pharmacotherapy, Semmelweis University, 1085 Budapest, Hungary.

Mario van der Stelt (M)

Department of Molecular Physiology, Leiden Institute of Chemistry, Leiden University, 2333 CC, Leiden, The Netherlands.
ORCID: 0000-0002-1029-5717

Pal Pacher (P)

National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Rockville, Maryland 20852, United States.

Jürg Gertsch (J)

Institute of Biochemistry and Molecular Medicine, University of Bern, 3012 Bern, Switzerland.

Peter J McCormick (PJ)

William Harvey Research Institute, Barts and the London School of Medicine, Queen Mary University of London, London EC1M 6BQ, England.

Christoph Ullmer (C)

Roche Pharma Research & Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., 4070 Basel, Switzerland.

Sergio Oddi (S)

Faculty of Veterinary Medicine, University of Teramo, 64100 Teramo, Italy.
European Center for Brain Research (CERC)/Santa Lucia Foundation, 00179 Rome, Italy.

Mauro Maccarrone (M)

European Center for Brain Research (CERC)/Santa Lucia Foundation, 00179 Rome, Italy.
Department of Applied Clinical and Biotechnological Sciences, University of L'Aquila, 67100 L'Aquila, Italy.

Dmitry B Veprintsev (DB)

Faculty of Medicine & Health Sciences, University of Nottingham, Nottingham NG7 2UH, U.K.
Centre of Membrane Proteins and Receptors (COMPARE), University of Birmingham and University of Nottingham, Midlands B15 2TT, U.K.
ORCID: 0000-0002-3583-5409

Marc Nazaré (M)

Leibniz-Institut für Molekulare Pharmakologie FMP, Campus Berlin-Buch, 13125 Berlin, Germany.
ORCID: 0000-0002-1602-2330

Uwe Grether (U)

Roche Pharma Research & Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., 4070 Basel, Switzerland.

Erick M Carreira (EM)

Laboratorium für Organische Chemie, Eidgenössische Technische Hochschule Zürich, Vladimir-Prelog-Weg 3, 8093 Zürich, Switzerland.
ORCID: 0000-0003-1472-490X

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Troubles mentaux › Troubles neurocognitifs › Démence › Maladie d'Alzheimer › Development of High-Specificity Fluorescent...
questionsmedicales.fr › Eucaryotes › Animaux › Development of High-Specificity Fluorescent...
questionsmedicales.fr › Cellules › Cellules épithéliales › Cellules CHO › Development of High-Specificity Fluorescent...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Arvicolinae › Cricetinae › Cricetulus › Development of High-Specificity Fluorescent...
questionsmedicales.fr › Techniques d'investigation › Modèles théoriques › Modèles biologiques › Modèles animaux de maladie humaine › Development of High-Specificity Fluorescent...
questionsmedicales.fr › Techniques d'investigation › Techniques cytologiques › Cytophotométrie › Cytométrie en flux › Development of High-Specificity Fluorescent...
questionsmedicales.fr › Phénomènes chimiques › Phénomènes biochimiques › Transfert d'énergie par résonance de fluorescence › Development of High-Specificity Fluorescent...
questionsmedicales.fr › Actions chimiques et utilisations › Utilisations spécialisées de produits chimiques › Produits chimiques de laboratoire › Indicateurs et réactifs › Luminescents › Colorants fluorescents › Development of High-Specificity Fluorescent...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Development of High-Specificity Fluorescent...
questionsmedicales.fr › Actions chimiques et utilisations › Utilisations spécialisées de produits chimiques › Produits chimiques de laboratoire › Ligands › Development of High-Specificity Fluorescent...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Development of High-Specificity Fluorescent...
questionsmedicales.fr › Cellules › Névroglie › Microglie › Development of High-Specificity Fluorescent...
questionsmedicales.fr › Sciences de l'information › Méthodologies informatiques › Simulation numérique › Simulation de docking moléculaire › Development of High-Specificity Fluorescent...
questionsmedicales.fr › Actions chimiques et utilisations › Utilisations spécialisées de produits chimiques › Produits chimiques de laboratoire › Sondes moléculaires › Development of High-Specificity Fluorescent...
questionsmedicales.fr › Techniques d'investigation › Imagerie optique › Development of High-Specificity Fluorescent...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Récepteurs de surface cellulaire › Récepteurs couplés aux protéines G › Récepteurs de cannabinoïdes › Récepteur cannabinoïde de type CB2 › Development of High-Specificity Fluorescent...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Statistiques comme sujet › Sensibilité et spécificité › Development of High-Specificity Fluorescent...
questionsmedicales.fr › Phénomènes physiologiques cellulaires › Transduction du signal › Development of High-Specificity Fluorescent...